Overcoming Pitfalls to Optimize Cushing’s Disease Diagnosis and Management

Saturday, March 20, 2021
Program: 5:30 PM – 7:00 PM EDT  

Expert faculty will discuss:
• Current guidelines and diagnostic testing performance in the diagnosis of Cushing’s disease
• Identification of recurrent Cushing’s disease and use of potential treatment strategies
• Current approved and off label pharmacologic therapies in the management of Cushing’s disease
• The latest safety, efficacy, and outcomes data in recent and ongoing clinical trials of emerging medical therapies for Cushing’s disease

This course is a virtual live CME-certified Ancillary Symposium to be presented at ENDO 2021. This educational activity is supported by an independent medical educational grant from Corcept Therapeutics Incorporated, HRA Pharma Rare Diseases and Recordati Rare Diseases Inc. This ancillary symposium is developed through the Endocrine Society’s Special Programs Committee (SPC).







Learning Objectives

Upon successful completion these educational sessions, participants should be better able to:
• Apply current guidelines and diagnostic testing performance in the diagnosis of Cushing’s disease.
• Identify recurrent Cushing’s disease and use of potential treatment strategies.
• Analyze current approved and off label pharmacologic therapies in the management of Cushing’s disease.
• Review current safety, efficacy, and outcomes data in recent and ongoing clinical trials of emerging medical therapies for Cushing’s disease.
• Evaluate patient cases during follow-up visits to optimize management of Cushing’s disease.

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Neuroendocrinology and Pituitary
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Course opens: 
Course expires: 

5:30 – 5:35 PM | Introduction, Pre-Test Polling | James W. Findling, MD

5:35 – 5:57 PM | Cushing’s Syndrome: Updates in Diagnostic Tests Performance (Including Pitfalls In Interpretation) | James W. Findling, MD

5:57 – 6:19 PM | Cushing’s Disease: Pharmacologic Treatment Updates – Patient Case (Generalist) | Richard J. Auchus, MD, PhD

6:19 – 6:41 PM | Cushing’s Syndrome: Summary of High Impact Clinical Trials | Susmeeta T. Sharma, MD

6:41 – 7:00 PM | Closing Remarks, Post-Test Polling, Q&A Session | All Faculty


James W. Findling, MD - Program Chair
Clinical Professor of Medicine and Surgery
Medical College of Wisconsin
Menomonee Falls, WI

Richard J. Auchus, MD, PhD
Professor of Internal Medicine
Professor of Pharmacology
James A Shayman and Andrea S Kevrick Professor of Translational Medicine
University of Michigan
Ann Arbor, MI

Susmeeta T. Sharma, MD
Director of Pituitary Endocrinology
MedStar Washington Hospital Center
Washington, DC


As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:

James W. Findling, MD: Consultant, Corcept Therapeutics, Recordati; Grant Recipient, Novartis Pharmaceuticals
Richard J. Auchus, MD, PhD: Consultant, Novartis Pharmaceuticals, Corcept Therapeutics, Jansen Pharmaceuticals, Quest Diagnostics, Strongbridge Biopharma, Crinetics Pharmaceuticals, Adrenas Therapeutics, PhaseBio Pharmaceuticals, OMass Therapeutics, Recordati Rare Diseases; Grant Recipient, Novartis Pharmaceuticals, Corcept Therapeutics, Neurocrine Biosciences, Spruce Biosciences
Susmeeta T. Sharma, MD: Research Investigator, Corcept Therapeutics

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:  Beret Anne Casey, MD

The following SPC Committee members reported financial relationships:

  • Andjela T. Drincic, MD: Advisory Board Member, Corcept
  • Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
  • Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences, ATA Board Member
  • Amy Rothberg, MD: Spouse, consultant of Merck
  • Katherine Araque, MD: Speaker, Novo Nordisk; Advisory Board, Corcept

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:

 Lorena Alarcon-Casa Wright, MD, Neena Natt, MD; Kelly Lauter Roszko, MD, PhD; Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

The staff involved in the development of this CME activity reported no relevant financial relationships.



The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.


When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


This educational activity is supported by independent medical educational grants from Corcept Therapeutics Incorporated, HRA Pharma Rare Diseases and Recordati Rare Diseases Inc. 

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credit:

The Endocrine Society designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC):

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.